Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
BLUE BLOOD BIOTECH CORPORATION has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This matter is handled by 1 distinct examiner in 1 distinct art unit. The concentration of the portfolio into a single art unit suggests a specific focus within the biotechnology field. This arrangement allows the company to tailor its prosecution strategy to the specific technical standards and procedural expectations of 1 distinct art unit.
The busiest examiner, MCMILLIAN, KARA RENITA, is responsible for 1 pending office action. As there is only 1 distinct examiner for the entire portfolio, the company's current prosecution strategy is focused on a single point of contact. This examiner manages the 1 pending office action, representing the entirety of the firm's active workload in this sector. Practitioners should note that the outcome of the pending matter depends on the specific examination style of MCMILLIAN, KARA RENITA. The presence of 1 distinct examiner and 1 distinct art unit simplifies the communication process but makes the success of this single action critical for the company's immediate patent goals.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MCMILLIAN, KARA RENITA | 1 | 30.9% | +37.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18404851 | METHOD AND SYSTEM FOR DELIVERING AN ACTIVE INGREDIENT BY INHALATION | MCMILLIAN, KARA RENITA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18404851 | METHOD AND SYSTEM FOR DELIVERING AN ACTIVE INGREDIENT BY INHALATION | MCMILLIAN, KARA RENITA | — |
| Art Unit | Apps |
|---|---|
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18404851 | METHOD AND SYSTEM FOR DELIVERING AN ACTIVE INGREDIENT BY INHALATION | MCMILLIAN, KARA RENITA | 1623 | §102§103§112 | Non-Final OA | — | Pending | Jan 04, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBLUE BLOOD BIOTECH CORPORATION has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Kara Renita Mcmillian has the most, with 1 of BLUE BLOOD BIOTECH CORPORATION's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
